- In March 2025, Samphire Neuroscience, a pioneer in neurotechnology, officially launched Nettle™, its CE-certified brain device designed to alleviate both mental and physical symptoms associated with menstruation. This initiative underscores the company's dedication to delivering innovative, non-pharmacological pain relief solutions tailored to the growing North America demand for alternative and technology-driven menstrual health management. By leveraging its expertise in transcranial direct current stimulation (tDCS), Samphire Neuroscience is not only addressing discomfort but also reinforcing its position in the rapidly expanding femtech and digital therapeutics market.
- In 2024, Bayer AG, strategically continued its focus on advancing treatments for endometriosis-associated pelvic pain, a significant cause of secondary dysmenorrhea in North America. This ongoing commitment, exemplified by the sustained research and commercialization of products like Visanne, underscores the company's dedication to delivering effective medical solutions tailored to complex gynecological pain conditions. By leveraging its extensive R&D capabilities and established pharmaceutical expertise, Bayer AG is not only addressing chronic pain but also reinforcing its dominant position in the rapidly evolving women's health sector.
